Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 28438473

Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2017 Jun
First author
Coleman RL

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2017 Jun;18(6):701-702. doi: 10.1016/S1470-2045(17)30253-X.
    note
    Source null
    related pmid
    28438475
    relationship
    Comment in

Authors and identifiers

  1. name
    Coleman RL
    type
    Author
  2. name
    Brady MF
    type
    Author
  3. name
    Herzog TJ
    type
    Author
  4. name
    Sabbatini P
    type
    Author
  5. name
    Armstrong DK
    type
    Author
  6. name
    Walker JL
    type
    Author
  7. name
    Kim BG
    type
    Author
  8. name
    Fujiwara K
    type
    Author
  9. name
    Tewari KS
    type
    Author
  10. name
    O'Malley DM
    type
    Author
  11. name
    Davidson SA
    type
    Author
  12. name
    Rubin SC
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Coleman RL
    type
    Author
  2. name
    Brady MF
    type
    Author
  3. name
    Herzog TJ
    type
    Author
  4. name
    Sabbatini P
    type
    Author
  5. name
    Armstrong DK
    type
    Author
  6. name
    Walker JL
    type
    Author
  7. name
    Kim BG
    type
    Author
  8. name
    Fujiwara K
    type
    Author
  9. name
    Tewari KS
    type
    Author
  10. name
    O'Malley DM
    type
    Author
  11. name
    Davidson SA
    type
    Author
  12. name
    Rubin SC
    type
    Author
bibliography ids
  1. nci-bib-a649dc776324b6683990ddaf
book metadata
content sha256
24e960cf1a7fac089068c41012f6c398ecc57763c4395365dd0bcb01ef06e358
document type
citation
dois
  1. 10.1016/S1470-2045(17)30279-6
electronic publication date
display
2017 Apr 21
precision
day
year
2017
evidence scope
bibliographic_metadata_only
id
pubmed:28438473
immutable id
pubmed:28438473@24e960cf1a7fac089068c41012f6c398ecc57763c4395365dd0bcb01ef06e358
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
6
name
The Lancet. Oncology
nlm unique id
100957246
pages
779-791
volume
18
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2017 Jun;18(6):701-702. doi: 10.1016/S1470-2045(17)30253-X.
    note
    Source null
    related pmid
    28438475
    relationship
    Comment in
outcomes validated
false
pmid
28438473
provenance
batch id
1c173f0e18be0c6d461b
provider
NCBI PubMed ESummary
record sha256
023d724aa4c98c6b8517944daf8e973a40adb726e8d2016b710b57927199dc4f
response sha256
27a6f8bb5d49a8d376b07e1b1768913c558986bf73de92cdd65c8f05a5fa1e61
retrieved at
2026-09-09T23:47:25.975513+00:00
publication date
display
2017 Jun
precision
month
year
2017
publication types
  1. Clinical Trial, Phase III
  2. Journal Article
  3. Multicenter Study
  4. Randomized Controlled Trial
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/28438473/
title
Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.

Preserved source evidence · Not medical advice